Twist Bioscience Corporation
NASDAQ:TWSTMedical - Diagnostics & Research
+$2.15 today
- Market cap
- $7.66B
- Beta
- 2.21
- P/E (TTM)
- -64.5
- EPS (TTM)
- -$1.32
Volume 2.23M
Average 1.53M
TWST Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Twist Bioscience CorporationNASDAQ: TWST
Free Cash Flow · Q4 FY2026 · quarter ended Sep 2026
Free cash flow dips below year-ago levels
Q4 FY2026 free cash flow of $20.13M (cash outflow) fell 17.0% year over year, behind the +17.7% change in trailing-twelve-month free cash flow. Sequentially, it rose 135.5% from the prior quarter. Over 3 fiscal years it compounded at -19.4% a year.
Context
- Free cash flow amounted to 19.4% of revenue in FY2026, down 0.7 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -17.0% toward the trailing-twelve-month pace of +17.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2026
- (89.01M) USD
- Year-over-year change
- -17.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | (89.01M) | -17.7% |
| FY2025 | 2025-09-30 | (75.63M) | -9.3% |
| FY2024 | 2024-09-30 | (69.17M) | +59.4% |
| FY2023 | 2023-09-30 | (170.25M) | +24.7% |
| FY2022 | 2022-09-30 | (226.24M) | — |
Free Cash Flow vs competitors
How TWST compares with its peers on the latest reported figures
- TWST's LTM Sep 2026 free cash flow of $89.01M is the smallest of the 2 companies compared; the peer median is $110.78M.
- Its year-over-year change of +17.7% is the highest of 2, against a peer median of +4.6%.
- Free cash flow amounts to 19.4% of revenue for TWST, versus a peer median of 14.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $110.78M | +4.6% | +34.3% | 14.1% | |
| LTM Sep 2026 | $89.01M | +17.7% | -19.4% | 19.4% | |
| Peer median (excluding TWST) | $110.78M | +4.6% | +34.3% | 14.1% | |
Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | (217.86M) | (204.62M) | (208.73M) | (77.67M) | (130.2M) |
| Depreciation & Amortization | 16.51M | 29.31M | 31.43M | 24.85M | 26.48M |
| Deferred Income Tax | 0 | (410K) | 0 | 0 | 0 |
| Stock-Based Compensation | 79.66M | 30.28M | 50.93M | 64.46M | 69.86M |
| Change in Working Capital | (5.36M) | (1.01M) | 15.41M | (12.61M) | (7.83M) |
| Accounts Receivables | (9.62M) | (4.32M) | 8.44M | (22.38M) | (13.8M) |
| Inventory | (7.54M) | 7.24M | 7.99M | (4.23M) | (18.1M) |
| Accounts Payables | 7.38M | (2.51M) | (11.81M) | 9.33M | 13.93M |
| Other Working Capital | 4.42M | (1.42M) | 10.79M | 4.67M | 10.14M |
| Other Non-Cash Items | 2.66M | 3.98M | 46.86M | (46.66M) | 265K |
| Operating Cash Flow | (124.39M) | (142.47M) | (64.09M) | (47.63M) | (41.43M) |
| Capital Expenditures | (101.86M) | (27.78M) | (5.08M) | (28M) | (47.58M) |
| Acquisitions (Net) | (8.16M) | 5.86M | 0 | 2.5M | 0 |
| Purchases of Investments | (217.64M) | (76.35M) | (51.91M) | (49.39M) | (47.9M) |
| Sales of Investments | 100.48M | 154.74M | 53.91M | 50.14M | 49.35M |
| Other Investing Activities | (5.76M) | (5.86M) | 0 | 0 | (6.95M) |
| Investing Cash Flow | (232.93M) | 50.61M | (3.07M) | (24.76M) | (53.09M) |
| Debt Repayment | (1.56M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 269.82M | 0 | 0 | 13.56M | 446.72M |
| Common Stock Repurchased | (7.75M) | (4.41M) | (3.98M) | (16K) | (42K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.02M | 5.32M | 10.87M | 15M | 0 |
| Financing Cash Flow | 270.53M | 911K | 6.89M | 28.54M | 446.68M |
| Effect of Forex Changes | (319K) | (27K) | 126K | 583K | 24K |
| Net Change in Cash | (87.1M) | (90.98M) | (60.15M) | (43.27M) | 352.18M |
| Free Cash Flow | (226.24M) | (170.25M) | (69.17M) | (75.63M) | (89.01M) |
Twist Bioscience Corporation
NASDAQ:TWST
Intrinsic Alpha fair value
Locked
Current Price
$116.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.